Wang, S.; Malebari, A.M.; Greene, T.F.; Kandwal, S.; Fayne, D.; Nathwani, S.M.; Zisterer, D.M.; Twamley, B.; O’Boyle, N.M.; Meegan, M.J.
Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000. Pharmaceuticals 2025, 18, 1218.
https://doi.org/10.3390/ph18081218
AMA Style
Wang S, Malebari AM, Greene TF, Kandwal S, Fayne D, Nathwani SM, Zisterer DM, Twamley B, O’Boyle NM, Meegan MJ.
Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000. Pharmaceuticals. 2025; 18(8):1218.
https://doi.org/10.3390/ph18081218
Chicago/Turabian Style
Wang, Shu, Azizah M. Malebari, Thomas F. Greene, Shubhangi Kandwal, Darren Fayne, Seema M. Nathwani, Daniela M. Zisterer, Brendan Twamley, Niamh M. O’Boyle, and Mary J. Meegan.
2025. "Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000" Pharmaceuticals 18, no. 8: 1218.
https://doi.org/10.3390/ph18081218
APA Style
Wang, S., Malebari, A. M., Greene, T. F., Kandwal, S., Fayne, D., Nathwani, S. M., Zisterer, D. M., Twamley, B., O’Boyle, N. M., & Meegan, M. J.
(2025). Correction: Wang et al. Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells. Pharmaceuticals 2023, 16, 1000. Pharmaceuticals, 18(8), 1218.
https://doi.org/10.3390/ph18081218
